by 
Anti-Neprilysin or neprilysin inhibitors are drugs used for the treatment of heart failure. They work by inhibiting the enzyme neprilysin, which breaks down peptides like natriuretic peptides that causes sodium and water excretion from the body. With the rising prevalence of cardiovascular diseases globally, the treatment paradigm of heart failure management has shifted to a combination of neprilysin inhibitors along with renin–angiotensin–aldosterone system inhibitors. This is due to superior efficacy demonstrated by the combination in reducing mortality and morbidity in patients with heart failure and reduced ejection fraction.
The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising geriatric population is a key driver bolstering the anti-Neprilysin market growth. As age increases, so does the risk of heart failure. For example, according to the Centers for Disease Control and Prevention (CDC), about 10 out of 1,000 people between ages 65 to 69 have heart failure, rising to 80 out of 1,000 for those age 80 and older. Furthermore, approval and launch of new neprilysin inhibitor drugs by companies provides lucrative opportunities. In 2021, the US FDA approved Daxxify (sacubitril and valsartan) tablets for the treatment of heart failure. It is the first anti-neprilysin drug approved for pediatric heart failure patients in the age group of 6 to <18 years.
Porter’s Analysis
Threat of new entrants: Low as this is a highly specialized market with high R&D and manufacturing costs. Bargaining power of buyers: Moderate as branded drugs have dependence but availability of substitutes provide options. Bargaining power of suppliers: Moderate as key inputs and manufacturing need specialized capabilities but high sourcing costs limit power. Threat of new substitutes: Moderate as new drug delivery methods and combination therapies pose threats but regulation delays new approvals. Competitive rivalry: High as major players compete aggressively on pricing, marketing and portfolio expansion.
Key Takeaways
The global Anti-Neprilysin market is expected to witness high growth over the forecast period of 2023 to 2030. Regionally, North America is expected to dominate the market over the forecast period owing to growing investments in R&D and presence of major players in the region. Europe is also anticipated to grow significantly during the forecast period.
Regional analysis – North America is projected to account for the largest share of the anti-neprilysin market during the forecast period due to increasing healthcare expenditures and a large number of ongoing clinical trials. The market in the Asia Pacific region is likely to grow at the highest CAGR owing to high unmet needs and improving healthcare infrastructure.
Key players – Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET is one of the leading players offering drugs for hypertension. Novartis AG has a diverse portfolio including neprilysin inhibitors.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
